葡萄糖类-1受体激活剂可以诱导喘吗? 对FAERS数据库的分析
Mario Cazzola1, Maria Gabriella Matera2, Luigino Calzetta3
1Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
概括
类似葡萄糖-1受体激动剂 (GLP1RAs) 可能与呼吸系统不良事件有关,包括喘. 某些GLP1RA在现实数据中显示出更高比例的喘相关事件,需要仔细的临床监测.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 呼吸系统医学 呼吸系统医学
- 药品安全监督 药品安全监督
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP1RAs) 用于2型糖尿病,但由于其抗炎作用,正在研究喘.
- 人们担心GLP1RAs可能诱发或加重喘症状.
研究的目的:
- 通过FDA的不良事件报告系统 (FAERS) 调查与GLP1RA治疗相关的喘报告.
主要方法:
- 来自美国食品和药物管理局 (FDA) 的不良事件 (AE) 报告系统 (FAERS) 数据的综述.
- 分析的重点是识别用GLP1RAs治疗的患者的喘或类似喘事件.
主要成果:
- 某些GLP1RAs,包括exenatide,semaglutide和liraglutide,与更高比例的呼吸系统AE相关,特别是喘或喘类事件.
- 在统计学上显著的关联被发现为semaglutide和liraglutide.
- 报告了严重的喘相关事件和死亡,其中埃克西纳提德死亡比例最高.
结论:
- 在GLP1RA中观察到的AE概况的差异尚未完全理解,可能涉及药物特性,患者因素和报告偏差.
- GLP1RAs的潜在呼吸风险需要仔细的临床监测.
- 进一步的研究至关重要,以了解GLP1RA益处与呼吸系统风险之间的相互作用,以提高患者安全.
相关概念视频
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
246
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
246
01:24Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
01:19Antiasthma Drugs: Leukotriene Modifiers
274
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
274
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
270
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
270
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K